MK-3868

MK-3868 is an investigational small molecule antimalarial agent developed by Merck & Co. (known as MSD outside the U.S. and Canada). It is currently in Phase 1 clinical development for the treatment and prevention of malaria. MK-3868 is designed as a dual inhibitor of Plasmepsin IX (Plm IX) and Plasmepsin X (Plm X), which are essential aspartic proteases in the *Plasmodium falciparum* parasite. These enzymes play critical roles in multiple stages of the parasite's life cycle, including the invasion of and egress from host erythrocytes. By inhibiting both Plm IX and Plm X, MK-3868 aims to provide potent antimalarial activity with a high genetic barrier to resistance. The drug is being evaluated for its safety, tolerability, and pharmacokinetic profile in healthy adult volunteers.